Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers

Overview

Journal Gastroenterology

Specialty Gastroenterology

Date 2015 Jul 29

PMID 26216839

Citations 376

Authors

Yoshinaga Okugawa

William M Grady

Ajay Goel

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. One of the fundamental processes driving the initiation and progression of CRC is the accumulation of a variety of genetic and epigenetic changes in colonic epithelial cells. Over the past decade, major advances have been made in our understanding of cancer epigenetics, particularly regarding aberrant DNA methylation, microRNA (miRNA) and noncoding RNA deregulation, and alterations in histone modification states. Assessment of the colon cancer "epigenome" has revealed that virtually all CRCs have aberrantly methylated genes and altered miRNA expression. The average CRC methylome has hundreds to thousands of abnormally methylated genes and dozens of altered miRNAs. As with gene mutations in the cancer genome, a subset of these epigenetic alterations, called driver events, are presumed to have a functional role in CRC. In addition, the advances in our understanding of epigenetic alterations in CRC have led to these alterations being developed as clinical biomarkers for diagnostic, prognostic, and therapeutic applications. Progress in this field suggests that these epigenetic alterations will be commonly used in the near future to direct the prevention and treatment of CRC.

Citing Articles

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.

Haynes J, Manogaran P Int J Mol Sci. 2025; 26(5).

PMID: 40076613 PMC: 11901061. DOI: 10.3390/ijms26051988.

New insights into tRNA-derived small RNAs in human digestive diseases.

Liu Y, Chen F, Zhang F, Ye Y, Su Y, Liu Y Mol Biol Rep. 2025; 52(1):295.

PMID: 40063289 DOI: 10.1007/s11033-025-10393-7.

Colorectal Cancer: Pathogenesis and Targeted Therapy.

Li J, Pan J, Wang L, Ji G, Dang Y MedComm (2020). 2025; 6(3):e70127.

PMID: 40060193 PMC: 11885891. DOI: 10.1002/mco2.70127.

Identification and functional characterization of m1A-related genes in colorectal cancer: implications for prognosis, immune infiltration, and therapeutic strategies.

Sun L, Huangfu L, Li F, Yan Y, Kong R, Ji K Front Oncol. 2025; 15:1532602.

PMID: 40040720 PMC: 11876182. DOI: 10.3389/fonc.2025.1532602.

Unveiling the prognostic significance of RNA editing-related genes in colon cancer: evidence from bioinformatics and experiment.

Deng Z, Jin X, Liu B, Zhen H, Wang X Eur J Med Res. 2025; 30(1):94.

PMID: 39940052 PMC: 11823094. DOI: 10.1186/s40001-025-02335-7.

References

Tamagawa H, Oshima T, Numata M, Yamamoto N, Shiozawa M, Morinaga S . Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. Eur J Surg Oncol. 2013; 39(6):655-61. DOI: 10.1016/j.ejso.2013.02.023. View

Du M, Liu S, Gu D, Wang Q, Zhu L, Kang M . Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients. Carcinogenesis. 2014; 35(12):2723-30. DOI: 10.1093/carcin/bgu189. View

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

Zhang H, Zhu Y, Wu Y, Zhang P, Qi J . Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. World J Gastroenterol. 2014; 20(20):6329-35. PMC: 4033472. DOI: 10.3748/wjg.v20.i20.6329. View

van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B . Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut. 2002; 51(6):797-802. PMC: 1773491. DOI: 10.1136/gut.51.6.797. View

Vickers K, Palmisano B, Shoucri B, Shamburek R, Remaley A . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4):423-33. PMC: 3074610. DOI: 10.1038/ncb2210. View

Schmitz K, Hey S, Schinwald A, Wohlschlaeger J, Baba H, Worm K . Differential expression of microRNA 181b and microRNA 21 in hyperplastic polyps and sessile serrated adenomas of the colon. Virchows Arch. 2009; 455(1):49-54. DOI: 10.1007/s00428-009-0804-0. View

Paone J, Waalkes T, Baker R, Shaper J . Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma. J Surg Oncol. 1980; 15(1):59-66. DOI: 10.1002/jso.2930150110. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

10.

He L, Hannon G . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31. DOI: 10.1038/nrg1379. View

11.

Park S, Kim S, Hong Y, Lee J, Kim J, Kim K . TFAP2E methylation status and prognosis of patients with radically resected colorectal cancer. Oncology. 2014; 88(2):122-32. DOI: 10.1159/000362820. View

12.

Bell J, Tsai P, Yang T, Pidsley R, Nisbet J, Glass D . Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population. PLoS Genet. 2012; 8(4):e1002629. PMC: 3330116. DOI: 10.1371/journal.pgen.1002629. View

13.

Nilsson T, Lof-Ohlin Z, Sun X . DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients. Int J Oncol. 2012; 42(1):127-33. PMC: 3583697. DOI: 10.3892/ijo.2012.1682. View

14.

Imperiale T, Ransohoff D, Itzkowitz S . Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014; 371(2):187-8. DOI: 10.1056/NEJMc1405215. View

15.

Wu C, Ng S, Dong Y, Tian L, Ng S, Leung W . Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma. Clin Cancer Res. 2014; 20(11):2994-3002. DOI: 10.1158/1078-0432.CCR-13-1750. View

16.

Uchida H, Ando H, Maruyama K, Kobayashi H, Toda H, Ogawa H . Genetic alterations of mixed hyperplastic adenomatous polyps in the colon and rectum. Jpn J Cancer Res. 1998; 89(3):299-306. PMC: 5921800. DOI: 10.1111/j.1349-7006.1998.tb00562.x. View

17.

Tanaka K, Shiota G, Meguro M, Mitsuya K, Oshimura M, Kawasaki H . Loss of imprinting of long QT intronic transcript 1 in colorectal cancer. Oncology. 2001; 60(3):268-73. DOI: 10.1159/000055328. View

18.

Rex D, Ahnen D, Baron J, Batts K, Burke C, Burt R . Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012; 107(9):1315-29. PMC: 3629844. DOI: 10.1038/ajg.2012.161. View

19.

Hur K, Toiyama Y, Schetter A, Okugawa Y, Harris C, Boland C . Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. J Natl Cancer Inst. 2015; 107(3). PMC: 4334826. DOI: 10.1093/jnci/dju492. View

20.

Lee S, Cho N, Choi M, Yoo E, Kim J, Kang G . Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int. 2008; 58(2):104-13. DOI: 10.1111/j.1440-1827.2007.02197.x. View